Answers are grounded in this paper and cite their sources.
Objectives: To investigate influencing factors and establish a nomogram for predicting the short-term efficacy of repeated intravesical platelet-rich plasma (PRP) injections in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome. Methods: We retrospectively analyzed 198 patients who completed 4 intravesical PRP injections between February 2023 and June 2025. Treatment efficacy was defined as a Global Response Assessment score ≥2 at 3 months posttreatment. Predictors were screened using least absolute shrinkage and selection operator regression, and a nomogram was constructed using multivariable logistic regression. Discrimination, calibration, and clinical utility were assessed using the area under the receiver operating characteristic curve (AUC), the Hosmer–Lemeshow test, and decision curve analysis, respectively. Bootstrap resampling (B = 1000) was used for internal validation, and a temporal cohort of 52 patients treated between July and December 2025 was used for validation. Results: Of the 198 patients (mean age 56.3 ± 9.5 years; 90.9% female), 127 (64.1%) achieved effective treatment. Longer disease duration (odds ratio [OR], 1.071, p < 0.001), elevated Self-Rating Anxiety Scale score (OR, 1.055, p = 0.001), and concomitant pelvic floor muscle spasm (OR, 7.147, p < 0.001) were risk factors for ineffectiveness; greater maximum bladder capacity (OR = 0.995, p = 0.019) and higher glomerulation grade (OR, 0.421, p = 0.004) were protective factors. The nomogram achieved an AUC of 0.940, with an optimism-corrected AUC of 0.931 (95% confidence interval, 0.897–0.971) and good calibration (Hosmer–Lemeshow χ 2 = 10.23, p = 0.249). Decision curve analysis showed positive net benefit across threshold probabilities of 0.10–0.70. In the temporal validation cohort, the AUC was 0.910 (95% confidence interval, 0.823–0.997). Conclusions: The nomogram demonstrated favorable predictive performance for short-term PRP efficacy in patients with non-Hunner-type interstitial cystitis/bladder pain syndrome and may serve as a decision-support tool for individualized treatment.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: